Lonza Posts Strong CDMO Performance In Q1 2025

Reuters
05/09
May 9 (Reuters) - LONZA GROUP AG ::
*STRONG CDMO^1 PERFORMANCE IN Q1 2025, IN LINE WITH EXPECTATIONS FOR FY 2025
*CDMO OUTLOOK 2025 CONFIRMED WITH CER^2 SALES GROWTH APPROACHING 20% AND CORE EBITDA MARGIN APPROACHING 30%
*CHI CONFIRMS ITS OUTLOOK TO RETURN TO LOW-TO-MID-SINGLE-DIGIT CER SALES GROWTH IN 2025 WITH AN IMPROVING CORE EBITDA MARGIN IN MID-TWENTIES
*MID-TERM OUTLOOK CONFIRMED
*Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS
*DOES NOT ANTICIPATE A MATERIAL FINANCIAL IMPACT FROM POTENTIAL TARIFFS
*LONZA NOW ANTICIPATES START OF OPERATIONS AT ITS NEW COMMERCIAL-SCALE ASEPTIC DRUG PRODUCT FACILITY IN STEIN (CH) IN 2027
*IN Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS
*CUSTOMER INTEREST IN VACAVILLE IS STRONG, WITH A THIRD LONG-TERM CUSTOMER CONTRACT SECURED AND A NUMBER OF CONTRACT NEGOTIATIONS ONGOING
*MAKING GOOD PROGRESS WITH PREPARATIONS FOR EXIT OF CHI BUSINESS
*CHI BUSINESS: CURRENTLY PLANNING NECESSARY CARVE-OUT MEASURES

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 09-MAY-202504:30:26.66 GMT

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10